Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis C

  Free Subscription


Articles published in Gastroenterology

Retrieve available abstracts of 78 articles:
HTML format
Text format



Single Articles


    November 2017
  1. LIU CJ, Chuang WL, Sheen IS, Wang HY, et al
    Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected with HBV.
    Gastroenterology. 2017 Nov 21. pii: S0016-5085(17)36369.
    PubMed     Text format     Abstract available


  2. SHERMAN KE, Shah VH
    Viral Hepatitis: Knowledge and Treatments for HBV/HCV and Associated Transplantation and Neoplasia.
    Gastroenterology. 2017 Nov 14. pii: S0016-5085(17)36348.
    PubMed     Text format    


  3. DIETZ J, Susser S, Vermehren J, Peiffer KH, et al
    Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment with Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 13. pii: S0016-5085(17)36353.
    PubMed     Text format     Abstract available


  4. DEBES JD, van Tilborg M, Groothuismink ZMA, Hansen BE, et al
    Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-acting Antivirals.
    Gastroenterology. 2017 Nov 1. pii: S0016-5085(17)36295.
    PubMed     Text format     Abstract available


    October 2017
  5. RATTAY T, Dumont P, Heinzow HS, Hutton DW, et al
    Cost-effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
    Gastroenterology. 2017 Oct 23. pii: S0016-5085(17)36275.
    PubMed     Text format     Abstract available


  6. JOHN M, Metwally M, Mangia A, Romero-Gomez M, et al
    TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.
    Gastroenterology. 2017 Oct 6. pii: S0016-5085(17)36134.
    PubMed     Text format    


  7. MONDELLI MU
    Liver MAIT Cells in Hepatitis C: Pathogenetic Role or Innocent Bystanders?
    Gastroenterology. 2017 Oct 4. pii: S0016-5085(17)36186.
    PubMed     Text format    


    September 2017
  8. CHILDS-KEAN LM, Hong J
    Detectable Viremia at the End of Treatment With Direct-Acting Antivirals Can Be Associated With Subsequent Clinical Cure in Patients With Chronic Hepatitis C: A Case Series.
    Gastroenterology. 2017 Sep 4. pii: S0016-5085(17)35912.
    PubMed     Text format    


    August 2017
  9. MAAN R, Feld JJ
    Risk for hepatocellular carcinoma after HCV antiviral therapy with direct-acting antivirals: case closed?
    Gastroenterology. 2017 Aug 31. pii: S0016-5085(17)36085.
    PubMed     Text format    


  10. YU ML
    Resistance-Associated Substitutions in Short Duration of Interferon-Free Direct-Acting Antivirals for Hepatitis C.
    Gastroenterology. 2017 Aug 3. pii: S0016-5085(17)35886.
    PubMed     Text format    


  11. BOLTE FJ, O'Keefe AC, Webb LM, Serti E, et al
    Intra-hepatic Depletion of Mucosal Associated Invariant T cells in Hepatitis C Virus-induced Liver Inflammation.
    Gastroenterology. 2017 Aug 2. pii: S0016-5085(17)35975.
    PubMed     Text format     Abstract available


    July 2017
  12. MISHRA P, Florian J, Peter J, Vainorius M, et al
    Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
    Gastroenterology. 2017 Jul 27. pii: S0016-5085(17)35956.
    PubMed     Text format    


  13. LENS S, Alvarado E, Marino Z, Londono MC, et al
    Effects of All-oral Anti-viral Therapy on HVPG and Systemic Hemodynamics in Patients with Hepatitis C Virus-associated Cirrhosis.
    Gastroenterology. 2017 Jul 19. pii: S0016-5085(17)35922.
    PubMed     Text format     Abstract available


    June 2017
  14. KANWAL F, Kramer J, Asch SM, Chayanupatkul M, et al
    Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents.
    Gastroenterology. 2017 Jun 19. pii: S0016-5085(17)35797.
    PubMed     Text format     Abstract available


  15. ENOMOTO M, Murakami Y, Kawada N
    Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35638.
    PubMed     Text format    


  16. DE MARCO L, Pellicano R
    When to Search for Occult Infection After Eradication of Hepatitis C?
    Gastroenterology. 2017 Jun 2. pii: S0016-5085(17)35601.
    PubMed     Text format    


    May 2017
  17. KANWAL F, Bacon BR, Beste LA, Brill JV, et al
    Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.
    Gastroenterology. 2017;152:1588-1598.
    PubMed     Text format    


  18. SINGH S, Muir AJ, Dieterich DT, Falck-Ytter YT, et al
    American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
    Gastroenterology. 2017;152:1544-1577.
    PubMed     Text format     Abstract available


    April 2017
  19. LAIDLAW SM, Marukian S, Gilmore RH, Cashman SB, et al
    Tumor Necrosis Factor Inhibits Spread of Hepatitis C Virus Among Liver Cells, Independent from Interferons.
    Gastroenterology. 2017 Apr 26. pii: S0016-5085(17)35530.
    PubMed     Text format     Abstract available


  20. JACOBSON IM, Lawitz E, Gane EJ, Willems BE, et al
    Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Gastroenterology. 2017 Apr 5. pii: S0016-5085(17)35399.
    PubMed     Text format     Abstract available


    March 2017
  21. JACOBSON IM, Lim JK, Fried MW
    AGA Institute Clinical Practice Update: Care of Patients Who Have Achieved a Sustained Virologic Response (SVR) Following Antiviral Therapy for Chronic Hepatitis C Infection.
    Gastroenterology. 2017 Mar 23. pii: S0016-5085(17)30327.
    PubMed     Text format     Abstract available


  22. MISHRA P, Chen M
    Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?
    Gastroenterology. 2017 Mar 18. pii: S0016-5085(17)30295.
    PubMed     Text format    


  23. SAADOUN D, Pol S, Ferfar Y, Alric L, et al
    Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 10. pii: S0016-5085(17)30269.
    PubMed     Text format     Abstract available


  24. COMARMOND C, Garrido M, Pol S, Desbois AC, et al
    Direct-acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-induced Cryoglobulinemia Vasculitis.
    Gastroenterology. 2017 Mar 5. pii: S0016-5085(17)30235.
    PubMed     Text format     Abstract available


    February 2017
  25. AGHEMO A, Colombo M
    Response-Guided Duration of Directly Acting Antiviral Therapy for Chronic Hepatitis C: Back to the Future?
    Gastroenterology. 2017 Feb 27. pii: S0016-5085(17)30205.
    PubMed     Text format    


  26. JACOBSON IM, Lawitz E, Kwo PY, Hezode C, et al
    Safety and Efficacy of Elbasvir/Grazoprevir in Patients with Hepatitis C Virus Infection and Compensated Cirrhosis: an Integrated Analysis.
    Gastroenterology. 2017 Feb 10. pii: S0016-5085(17)30150.
    PubMed     Text format     Abstract available


  27. MATSUURA K, Sawai H, Ikeo K, Ogawa S, et al
    Genome-wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
    Gastroenterology. 2017 Feb 2. pii: S0016-5085(17)30130.
    PubMed     Text format     Abstract available


  28. RAVI S, Axley P, Jones D, Kodali S, et al
    Unusually High Rates of Hepatocellular Carcinoma After Treatment With Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis.
    Gastroenterology. 2017 Feb 1. pii: S0016-5085(16)35535.
    PubMed     Text format    


    January 2017
  29. GANE EJ, Hyland RH, Yang Y, Svarovskaia E, et al
    Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
    Gastroenterology. 2017 Jan 27. pii: S0016-5085(17)30074.
    PubMed     Text format     Abstract available


  30. GOLDBERG D, Ditah IC, Saeian K, Lalehzari M, et al
    Changes in the Prevalence of Hepatitis C Virus Infection, Non-alcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
    Gastroenterology. 2017 Jan 11. pii: S0016-5085(17)30014.
    PubMed     Text format     Abstract available


    December 2016
  31. KOUTSOUDAKIS G, Perez-Del-Pulgar S, Forns X
    Occult Hepatitis C Virus Infection: Are We Digging Too Deep?
    Gastroenterology. 2016 Dec 27. pii: S0016-5085(16)35528.
    PubMed     Text format    


  32. BOSON B, Denolly S, Turlure F, Chamot C, et al
    Daclatasvir Prevents Hepatitis C Virus by Blocking Transfer of Viral Genome to Assembly Sites.
    Gastroenterology. 2016 Dec 5. pii: S0016-5085(16)35447.
    PubMed     Text format     Abstract available


    November 2016
  33. COLPITTS CC, Baumert TF
    SMAD about HCV cell entry and pathogenesis of liver disease.
    Gastroenterology. 2016 Nov 23. pii: S0016-5085(16)35398.
    PubMed     Text format    


  34. DONNELLY MC, Imlach SN, Abravanel F, Ramalingam S, et al
    Sofosbuvir and Daclatasvir Anti-Viral Therapy Fails to Clear HEV Viremia and Restore Reactive T Cells in a HEV/HCV Co-Infected Liver Transplant Recipient.
    Gastroenterology. 2016 Nov 21. pii: S0016-5085(16)34895.
    PubMed     Text format    


  35. ELMASRY S, Wadhwa S, Bang BR, Cook L, et al
    Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
    Gastroenterology. 2016 Nov 9. pii: S0016-5085(16)35323.
    PubMed     Text format     Abstract available


  36. WANG W, Hakim MS, Nair VP, de Ruiter PE, et al
    Distinct Antiviral Potency of Sofosbuvir against Hepatitis C and E Viruses.
    Gastroenterology. 2016 Nov 1. pii: S0016-5085(16)35194.
    PubMed     Text format    


    October 2016
  37. KOMATSU TE, Boyd S, Sherwat A, Tracy L, et al
    Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.
    Gastroenterology. 2016 Oct 20. pii: S0016-5085(16)35241.
    PubMed     Text format     Abstract available


  38. LIANG TJ
    Hepatitis C Virus: from Obscurity to the Lasker.
    Gastroenterology. 2016 Oct 17. pii: S0016-5085(16)35233.
    PubMed     Text format    


  39. KWO P, Gane E, Peng CY, Pearlman B, et al
    Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection.
    Gastroenterology. 2016 Oct 5. pii: S0016-5085(16)35170.
    PubMed     Text format     Abstract available


  40. AGHEMO A, Buti M
    Hepatitis C Therapy: Game Over!
    Gastroenterology. 2016 Oct 1. pii: S0016-5085(16)35131.
    PubMed     Text format    


    September 2016
  41. ZHANG F, Sodroski C, Cha H, Li Q, et al
    Infection of Hepatocytes with HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Upregulating SMAD6 and SMAD7.
    Gastroenterology. 2016 Sep 29. pii: S0016-5085(16)35128.
    PubMed     Text format     Abstract available


  42. NAHON P, Bourcier V, Layese R, Audureau E, et al
    Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
    Gastroenterology. 2016 Sep 15. pii: S0016-5085(16)35070.
    PubMed     Text format     Abstract available


    August 2016
  43. PAWLOTSKY JM
    Hepatitis C Drugs: Is Next Generation the Last Generation?
    Gastroenterology. 2016 Aug 30. pii: S0016-5085(16)34985.
    PubMed     Text format    


  44. TERRAULT NA, Zeuzem S, Di Bisceglie AM, Lim JK, et al
    Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated of Sustained Virologic Response.
    Gastroenterology. 2016 Aug 23. pii: S0016-5085(16)34927.
    PubMed     Text format     Abstract available


    July 2016
  45. LAWITZ E, Reau N, Hinestrosa F, Rabinovitz M, et al
    Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with Genotype 1 Hepatitis C Virus Infection in an Open-label, Phase 2 Trial.
    Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34835.
    PubMed     Text format     Abstract available


  46. GANE E, Kowdley KV, Pound D, Stedman CA, et al
    Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients with HCV Genotype 2, 3, 4, or 6 Infections in an Open-label, Phase 2 Trial.
    Gastroenterology. 2016 Jul 30. pii: S0016-5085(16)34834.
    PubMed     Text format     Abstract available


  47. AFDHAL NH, Serfaty L
    Cohort Studies and Registries in the treatment of HCV; the impact of "real life" effectiveness.
    Gastroenterology. 2016 Jul 22. pii: S0016-5085(16)34820.
    PubMed     Text format    


  48. GANE E, Poordad F, Wang S, Asatryan A, et al
    High Efficacy of ABT-493 and ABT-530 in Patients with HCV Genotype 1 or 3 Infection and Compensated Cirrhosis.
    Gastroenterology. 2016 Jul 22. pii: S0016-5085(16)34816.
    PubMed     Text format     Abstract available


  49. RAMIREZ S, Mikkelsen LS, Gottwein JM, Bukh J, et al
    Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Gastroenterology. 2016 Jul 21. pii: S0016-5085(16)34809.
    PubMed     Text format     Abstract available


  50. SHIN JY, Azoulay L, Filion KB
    Statin Use in Patients With Hepatitis C-related Cirrhosis: True Benefit or Immortal Time Bias?
    Gastroenterology. 2016 Jul 1. pii: S0016-5085(16)34434.
    PubMed     Text format    


    June 2016
  51. GAMBATO M, Perez-Del-Pulgar S, Hedskog C, Svarovskia ES, et al
    HCV RNA Persists in Liver Explants of Most Patients Awaiting Liver Transplantation Treated With an Interferon-Free Regimen.
    Gastroenterology. 2016 Jun 30. pii: S0016-5085(16)34697.
    PubMed     Text format     Abstract available


  52. SARRAZIN C, Dvory-Sobol H, Svarovskaia ES, Doehle B, et al
    Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment with Ledipasvir and Sofosbuvir.
    Gastroenterology. 2016 Jun 10. pii: S0016-5085(16)34614.
    PubMed     Text format     Abstract available


  53. IOANNOU GN, Beste LA, Chang MF, Green PK, et al
    Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Healthcare System.
    Gastroenterology. 2016 Jun 4. pii: S0016-5085(16)34575.
    PubMed     Text format     Abstract available


    May 2016
  54. GANE EJ, Schwabe C, Hyland RH, Yang Y, et al
    Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-naive or Previously Treated Patients with HCV Genotype 1 or 3 Infections.
    Gastroenterology. 2016 May 27. pii: S0016-5085(16)34513.
    PubMed     Text format     Abstract available


  55. KLINGE MJ, Borhani AA, Malik SM
    Hepatitis C and Numerous Disappearing Hepatic Nodules: No-dule C It, No-dule Don't.
    Gastroenterology. 2016 May 27. pii: S0016-5085(16)30099.
    PubMed     Text format    


    April 2016
  56. PAWLOTSKY JM
    Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens.
    Gastroenterology. 2016 Apr 11. pii: S0016-5085(16)30055.
    PubMed     Text format     Abstract available


    March 2016
  57. DI MARCO V, Calvaruso V, Ferraro D, Bavetta MG, et al
    Effects of Viral Eradication in Patients with HCV and Cirrhosis Differ With Stage of Portal Hypertension.
    Gastroenterology. 2016 Mar 31. pii: S0016-5085(16)30049.
    PubMed     Text format     Abstract available


  58. AGHEMO A, Colombo M
    No Time for Bullies in Hepatitis C Virus Therapy: Genotype 3 Conquered?
    Gastroenterology. 2016 Mar 24. pii: S0016-5085(16)00378.
    PubMed     Text format    


  59. POCKROS PJ, Reddy KR, Mantry PS, Cohen E, et al
    Efficacy of Direct-acting Antiviral Combination for Patients with HCV Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
    Gastroenterology. 2016 Mar 11. pii: S0016-5085(16)00326.
    PubMed     Text format     Abstract available


    February 2016
  60. YOUNOSSI Z, Park H, Henry L, Adeyemi A, et al
    Extra-Hepatic Manifestations of Hepatitis C-a Meta-Analysis of Prevalence, Quality of Life, and Economic Burden.
    Gastroenterology. 2016 Feb 25. pii: S0016-5085(16)00230.
    PubMed     Text format     Abstract available


  61. HASSAN T, Khan F, Kyprianou A
    A Not So Benign Abdomen!
    Gastroenterology. 2016;150:e1-2.
    PubMed     Text format    


    January 2016
  62. XIA Y, Stadler D, Lucifora J, Reisinger F, et al
    Interferon-gamma and Tumor Necrosis Factor-alpha Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.
    Gastroenterology. 2016;150:194-205.
    PubMed     Text format     Abstract available


    November 2015
  63. RAZIORROUH B, Sacher K, Tawar RG, Emmerich F, et al
    Virus-specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-helper Cells in Patients With Acute and Chronic HCV Infections.
    Gastroenterology. 2015 Nov 13. pii: S0016-5085(15)01622.
    PubMed     Text format     Abstract available


    October 2015
  64. WHITE DL, Richardson P, Tayoub N, Davila JA, et al
    The Updated Model: An Adjusted Serum Alpha-Fetoprotein-Based Algorithm for Hepatocellular Carcinoma Detection With Hepatitis C Virus-Related Cirrhosis.
    Gastroenterology. 2015 Oct 28. pii: S0016-5085(15)01435.
    PubMed     Text format    


  65. SULKOWSKI MS, Vargas HE, Di Bisceglie AM, Kuo PA, et al
    Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection.
    Gastroenterology. 2015 Oct 21. pii: S0016-5085(15)01507.
    PubMed     Text format     Abstract available


  66. MOHANTY A, Tate J, Garcia-Tsao G
    Statins are Associated with a Decreased Risk of Decompensation and Death in Veterans with Hepatitis C-related Compensated Cirrhosis.
    Gastroenterology. 2015 Oct 17. pii: S0016-5085(15)01476.
    PubMed     Text format     Abstract available


    September 2015
  67. BACK DJ, Burger DM
    Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: Potential mechanisms and lessons to be learned.
    Gastroenterology. 2015 Sep 25. pii: S0016-5085(15)01387.
    PubMed     Text format    


  68. FAUVELLE C, Felmlee DJ, Crouchet E, Lee J, et al
    Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
    Gastroenterology. 2015 Sep 21. pii: S0016-5085(15)01358.
    PubMed     Text format     Abstract available


  69. PETTA S, Maida M, Macaluso FS, Barbara M, et al
    Hepatitis C Virus Infection is Associated With Increased Cardiovascular Mortality: A Meta-analysis of Observational Studies.
    Gastroenterology. 2015 Sep 16. pii: S0016-5085(15)01322.
    PubMed     Text format     Abstract available


    August 2015
  70. NEGRO F, Forton D, Craxi A, Sulkowski MS, et al
    Extra-hepatic Morbidity and Mortality of Chronic Hepatitis C.
    Gastroenterology. 2015 Aug 25. pii: S0016-5085(15)01203.
    PubMed     Text format     Abstract available


  71. GANE EJ, Hyland RH, An D, Svarovskaia E, et al
    Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection.
    Gastroenterology. 2015 Aug 7. pii: S0016-5085(15)01096.
    PubMed     Text format     Abstract available


  72. BESTE LA, Leipertz SL, Green PK, Dominitz JA, et al
    Trends in the burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US Veterans from 2001-2013.
    Gastroenterology. 2015 Aug 5. pii: S0016-5085(15)01088.
    PubMed     Text format     Abstract available


  73. FOSTER GR, Pianko S, Brown A, Forton D, et al
    Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-alfa in Patients With HCV Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and HCV Genotype 2 Infection.
    Gastroenterology. 2015 Aug 3. pii: S0016-5085(15)01069.
    PubMed     Text format     Abstract available


  74. HSU YC, Wu CY
    Reply.
    Gastroenterology. 2015;149:501-2.
    PubMed     Text format    


    July 2015
  75. LAWITZ E, Makara M, Akarca US, Thuluvath PJ, et al
    Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-label Study of Patients With Genotype 1b Chronic Hepatitis C Virus, With and Without Cirrhosis.
    Gastroenterology. 2015 Jul 10. pii: S0016-5085(15)00936.
    PubMed     Text format     Abstract available


    June 2015
  76. AGHEMO A, Colombo M
    Will the Benefits of Treatment for Chronic Hepatitis C Be Retained in the Interferon-free Era?
    Gastroenterology. 2015 Jun 27. pii: S0016-5085(15)00894.
    PubMed     Text format    


    May 2015
  77. MONDELLI MU
    Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C.
    Gastroenterology. 2015 May 26. pii: S0016-5085(15)00720.
    PubMed     Text format    


  78. CHARLTON M, Everson GT, Flamm SL, Kumar P, et al
    Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease.
    Gastroenterology. 2015 May 15. pii: S0016-5085(15)00682.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: